From October 2011 to February 2013 Crizotinib was my go-to targeted therapy. We had a good run but like all things, it has come to an end.
After careful evaluation of my February 13th chest and liver CT scan, it is determined that I have progressed on Crizotinib. The amount of progression necessitates a change in treatment – bye-bye, Criz! Our last encounter, Valentine’s Day, was a good day to end a no longer mutually beneficial relationship.
Staying 100% focused on WBR after getting the “progression news” was troublesome. Yet, I needed to keep my head in the WBR game. If I could not make it through WBR my future chemo would mean squat. Dr S did an excellent job of communicating with me about forthcoming chemo options and not stressing me out. Have I told you lately how grand he is? He is.
The next step is a tad up-in-the-air, nonetheless worthy of announcing to the greater good! I’m fairly certain that it will come to full fruition; like hair growth in a few months. Later this week, SW and I are headed to Washington’s Seattle Cancer Care Alliance to discuss the LDK378 trial with Dr Renato Martins.
LDK378 is a drug sponsored by Novartis Pharmaceuticals. The trial that has my interest is titled: LDK378 in Adult Patients with ALK-activated NSCLC previously treated with Chemotherapy and Crizotinib. This is a Phase 2 trial where the testing protocol is established. What that all means? I’ll have to let you know. This IS my first rodeo.
The LDK378 trial, or any trial for that matter, will be a brand new world for me. Thankfully it is not brand new to the rest of the world. I am cautions and optimistic. For the most part, that’s how I roll. Thank you body for not developing resistance to antidepressants!